Fraternal twins with autism: Is risk in the womb? (AP)

CHICAGO � Most of the risk of autism has been blamed by experts on inherited genes. Now one of the largest studies of twins and autism shifts the focus to the womb, suggesting that the mother's age and health may play a larger role than thought.

The new research doesn't solve the mystery of what causes autism. Most scientists think faulty genes and outside factors are both at work. And since autism spectrum disorders include a wide range of conditions, from mild to severe, it's unlikely there's a single cause for all of them.

Conditions during pregnancy may trigger autism where there's a genetic vulnerability, said Dr. Gary Goldstein of the Kennedy Krieger Institute in Baltimore, who was not involved in the new research.

"We've identified lots of vulnerability genes, but not everybody who has them gets autism," Goldstein said.

The new twins study, published Monday by Archives of General Psychiatry, used rigorous methods to diagnose autism spectrum disorders, including direct observation of the children.

Using California health records, it's the largest study to do that and the first to consider a large sample of twins drawn from a general population, said lead author Dr. Joachim Hallmayer of Stanford University in Palo Alto, Calif.

Children with autism can have trouble communicating and interacting socially. They may have poor eye contact and engage in repetitive behavior such as rocking or hand-flapping. One in 100 children have autism disorders, according to U.S. government estimates.

The new study included 192 sets of twins where at least one of the twins was affected with autism.

Some of the twins were identical and some were non-identical, or fraternal, twins.

The researchers used DNA testing to determine which twins were identical and which were fraternal. That was important because identical twins come from one fertilized egg and have identical genetic makeups. Fraternal twins, from two fertilized eggs, share no more genetic material than any other siblings.

The new study found, as expected, high rates of shared autism disorders for identical twins: 77 percent of male twin pairs and 50 percent for female pairs had autism in both twins.

Surprisingly, it also found fairly high rates of fraternal twins both having autism spectrum disorders: 31 percent rate for male fraternal twins and 36 percent for female fraternal twins.

Other studies have found 10 to 20 percent of younger siblings of children with autism are likely to be diagnosed themselves with the disorder.

Fraternal twins share the same womb, even though they don't share identical genes. That could be important, said Dr. John Constantino of Washington University School of Medicine in St. Louis, who wasn't involved in the new research.

"Finding so many fraternal twin pairs in whom both twins have autism spectrum disorders is a key finding that puts a spotlight on pregnancy as a time when environmental factors might exert their effects," Constantino said.

Those factors could include stress, diet, infections, a mother's age and medications, experts said. The new study didn't try to determine what factors increase risk.

The study was funded by grants from the National Institute of Mental Health and Autism Speaks, an advocacy group.

In another study published Monday in the same journal, researchers found a higher risk of autism among children born to mothers who took antidepressants during the year before birth, particularly in the first three months of pregnancy.

It's too early to advise pregnant women against antidepressants, however. Untreated depression also can be harmful to mother and baby, said lead author Lisa Croen of the Autism Research Program at Kaiser Permanente, a large health maintenance organization in California.

___

Online:

Journal: http://archpsyc.ama-assn.org/

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials

Heart disease, No. 1 killer, can sneak up on women (AP)

WASHINGTON � Heart disease can sneak up on women in ways that standard cardiac tests can miss.

It's part of a puzzling gender gap: Women tend to have different heart attack symptoms than men. They're more likely to die in the year after a first heart attack.

In fact, more than 40 percent of women still don't realize that heart disease is the No. 1 female killer. One in 30 women's deaths in 2007 was from breast cancer, compared to about 1 in 3 from cardiovascular disease, according to the American Heart Association.

A new report says there's been too little progress in tackling the sex differences in heart disease. It outlines the top questions scientists must answer to find the best ways to treat women's hearts � and protect them in the first place.

"A woman's heart is her major health threat, and everyone who takes care of a woman has to realize that," says Emory University cardiologist Dr. Nanette Wenger, who co-authored the report.

Make no mistake: Heart disease is the leading killer of men, too. The illness is more prevalent in men, and tends to hit them about a decade earlier than is usual for women.

But while overall deaths have been dropping in recent years, that improvement has been slower for women who face some unique issues, says the report from the nonprofit Society for Women's Health Research and WomenHeart: The National Coalition for Women with Heart Disease.

Sure, being a couch potato and eating a lot of junk food is bad for a woman's heart just like a man's. High cholesterol will clog arteries. High blood pressure can cause a stroke.

But here's one problem: Even if a test of major heart arteries finds no blockages, at-risk women still can have a serious problem � something called coronary microvascular disease that's less common in men. Small blood vessels that feed the heart become damaged so that they spasm or squeeze shut, Wenger explains.

Specialists who suspect microvascular disease prescribe medications designed to make blood vessels relax and blood flow a bit better, while also intensively treating the woman's other cardiac risk factors. But Wenger says it's not clear what the best treatments are.

The report says part of the lack of understanding about such gender issues is because heart-related studies still don't focus enough on women, especially minority women. Only a third of cardiovascular treatment studies include information on how each gender responds even though federal policy says they should. The report urged direct comparisons of which treatments work best in women, and improved diagnostic tests.

Another issue: Even young women sometimes have a heart attack, and there are troubling hints that their risks are rising. There's been a small uptick in deaths among women younger than 45. Plus, high blood pressure, diabetes or related complications during pregnancy � a growing worry as more women start their pregnancies already overweight � aren't just a temporary problem but increase those mothers' risk of heart disease once they reach middle age. The report says too few doctors are aware they should consider that.

Then there are the questions of how best to tell which women are at high risk. Nearly two-thirds of women who die suddenly of heart disease report no previous symptoms, for example, compared with half of men. As for heart attacks, chest pain is the most common symptom but women are more likely than men to experience other symptoms such as shortness of breath, nausea and pain in the back or jaw.

Legislation pending in Congress would require better study of gender differences, and would expand a government program that currently screens poor women in 20 states for high cholesterol and other heart risks, offering smoking cessation and nutrition education to help lower those risks. Wenger's groups, which receive some funding from drug companies, and the heart association support the bill.

One young patient says women need to know more about heart disease � and to get pushy about any symptoms.

Essence Harris of New Orleans was just 30 and seemingly healthy when she started getting short of breath and feeling a flutter in her chest during her daily workouts. Her primary care doctor thought it was panic attacks. A cardiologist found no obvious risk either � her cholesterol and blood pressure were normal � but ordered a stress test that signaled her heart fears were right. A further exam found severe blockages in two arteries that required stents to prop open.

Now 37, Harris says doctors' best guess is that a stressful lifestyle � a single mother, a full-time job, a part-time personal trainer, and studying for an advanced degree all at the same time � left her vulnerable even without obvious risk factors. Had she not been so fit, they said, her heart might not have held out as long before symptoms appeared. She's learned to be more laid-back, along with a healthier diet and keeping up that exercise.

"Listen to your body," she advises other women. "Nobody knows you better than you."

___

EDITOR'S NOTE � Lauran Neergaard covers health and medical issues for The Associated Press in Washington.

Online:

Women and heart disease info: http://www.womenheart.org

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials

France records first E. coli death (AP)

PARIS � Authorities have recorded France's first death from the European E. coli outbreak.

Health officials in Bordeaux said the 78-year-old woman died early Saturday morning.

She had been hospitalized in Bordeaux since June 24 with hemolytic uremic syndrome � the rare kidney condition that the most seriously ill victims of the outbreak are suffering from.

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials

Under pressure, Idaho producer recalls sprouts (AP)

WASHINGTON � An Idaho sprout producer has recalled its alfalfa and spicy sprouts because they may be linked to 21 cases of salmonella poisoning.

Evergreen Produce of Moyie Springs, Idaho, initially refused to recall its sprouts after the Food and Drug Administration said the sprouts may be linked to the illnesses in Idaho, Montana, Washington state, North Dakota and New Jersey.

But the company relented under agency pressure.

The FDA warned people on Monday not to eat the sprouts.

Salmonella is an organism that can cause serious and sometimes fatal infections in people with weakened immune systems.

Raw sprouts often cause foodborne illness because they're grown in moist, warm conditions that bacteria enjoy.

An unrelated European E. coli outbreak believed to be caused by sprouts has killed 49 people and sickened 4,000.

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials

Medicare confirms payment for prostate cancer drug (AP)

WASHINGTON � Medicare officials confirmed Thursday that the program will cover the $93,000 price tag for prostate cancer drug Provenge, an innovative therapy that typically gives men suffering from an incurable stage of the disease an extra four months to live.

The decision from the Centers for Medicare and Medicaid essentially reiterates an earlier proposed ruling that the biotech drug, made by Dendreon Corp., is a "reasonable and necessary" medicine. As expected, the government will cover the cost for men who meet the drug's approved criteria: those with prostate disease that has spread throughout the body and has not responded to hormone therapy or radiation. The government will not pay for alternate, or so called "off-label," use.

"We do not believe there is any persuasive evidence for the off-label use," of Provenge, the agency concluded in the ruling, posted online late Thursday.

About 240,000 new cases of prostate cancer are diagnosed each year in the U.S. and the disease claims over 33,000 lives annually, according to the American Cancer Society. The decision ensures that tens of thousands of men will be able to take the drug through the government-backed health care plan that covers seniors. With government reimbursement, analysts estimate Provenge could rack up $1 billion in sales next year. The decision is important for Dendreon because most prostate cancer patients are 65 or older.

The infused drug is a first-of-a-kind treatment in that each dose is customized to work with each individual patient's immune system. The drug is given in three infusions over the course of one month.

Medicare is legally prohibited from considering price when deciding whether to pay for a new treatment. But Provenge's steep price tag had generated debate about the cost of new drugs and the government's role in paying for them, especially against the political backdrop of health care reform and the rising cost of Medicare given the large number of baby boomers.

Seattle-based Dendreon says Provenge's price reflects the more than $1 billion spent researching and developing the drug. And prostate cancer patients point out that the median survival time with Provenge is double that of chemotherapy, which is about two months and is marked by painful side effects.

Each regimen of Provenge must be tailored to the immune system of the individual patient using a time-consuming formulation process. Doctors collect special blood cells from each patient that help the immune system recognize cancer as a threat. The cells are mixed with a protein found on most prostate cancer cells and another substance to rev up the immune system, and then given back to the patient as three infusions two weeks apart.

Provenge is the first federally-approved cancer drug that uses the body's own immune system to fight the disease, offering an alternative to chemotherapy drugs that attack cancerous and healthy cells at the same time.

On Wednesday, Dendreon announced it received federal regulatory approval to open a second manufacturing facility in Los Angeles, in addition to its primary facility in New Jersey. The company hopes to open a third facility in Atlanta by the end of August.

Shares of Dendreon rose 96 cents, or 2.4 percent, to $40.40 in afterhours trading. The stock had closed the regular session down $1.06, or 2.6 percent, at $39.44.

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials

17 infants die in 48 hours at 1 Indian hospital (AP)

NEW DELHI � At least 17 infants have died in the last 48 hours at a government-run hospital in eastern India and the state is investigating, media reported Thursday.

Television news channels showed images of weeping and wailing parents outside the B.C. Roy Hospital for Children in Kolkata, the capital of West Bengal.

The hospital head D. Pal told Press Trust of India the babies were either premature, suffering from septicemia or had low birth weight problems. He denied any negligence by the hospital.

PTI quoted the state's top elected official, Mamata Banerjee, as saying her government had ordered an investigation.

In 2006, 22 infants died in three days at the same hospital because of prematurity or acute forms of either meningitis, encephalitis or septicemia, the hospital said at the time.

State-run hospitals in India are often overcrowded and ill-equipped to manage the large number of patients that come to them desperate for medical care.

India's infant mortality rate is higher than the world average. It ranks 50th of 222 countries and territories, with about 48 deaths per 1,000 live births estimated this year, according to the CIA World Factbook.

Powered By WizardRSS.com | Full Text RSS Feed | Amazon Plugin | Settlement Statement | WordPress Tutorials